Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical ...
Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license fees and milestone payments. Received $1 million milestone payment for animal-free recombinant albumin ...
“We believe our third quarter achievements underscore Dyadic’s commitment to leveraging our proprietary Dapibus™ and C1 microbial protein production platforms to drive immediate and ...
Dyadic International, Inc. (NASDAQ:DYAI) Q3 2024 Earnings Call Transcript November 16, 2024 Operator: Operator: Good evening, and welcome to Dyadic International Q3 2024 Conference Call.
This webpage provides information about the research project “Methods for the Analysis of Longitudinal Dyadic Data, with Applications to Intergenerational Exchanges of Family Support”. The three-year ...
Dyadic International Inc. ( (DYAI)) has released its Q3 earnings. Here is a breakdown of the information Dyadic International Inc. presented to its investors. Dyadic International, Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
We are looking for older couples who want to have a healthy lifestyle despite COVID-19. This study aims to compare two different methods of online interventions to change eating and physical activity ...
Dyadic International (DYAI) announced that it has been awarded a $3M grant from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus ...
Dyadic International Inc (NASDAQ:DYAI) reported a significant increase in revenue for Q3 2024, reaching approximately $1,958,000 compared to $397,000 for the same period a year ago. The company has ...